2024 Europe Sexually-Transmitted Disease (STD) Market: Shares and Segment Forecasts--AIDS/HIV, Chancroid, Chlamydia, Gonorrhea, Granuloma Inguinale, Herpes I/II, Lymphogranuloma, Mycoplasma, Papillomavirus, Syphilis, Trichomonas Vaginalis
This new report from LeadingMarketResearch.com contains analysis of the European sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.The report is available by section, and can be customized to specific information needs and budget.The report presents detailed analysis of the STD market in the France, Germany, Italy, Spain, and UK. Current scientific views on epidemiology and etiology are presented for:AIDS/HIV
Chancroid
Chlamydia
Gonorrhea
Granuloma Inguinale
Herpes I/II
Lymphogranuloma
Mycoplasma
Papillomavirus
Syphilis
Trichomonas VaginalisThe report provides test volume and sales forecasts by country and market segment, including:%li%Hospitals%li%Commercial/Private Labs%li%Public Health LabsIn addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of STD diagnostic products, by test and country. Also, the report examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies%li%Reviews features and operating characteristics of major analyzers used for STD testing; %li%Profiles key suppliers and potential market entrants developing innovative technologies and products; and analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues.MethodologyThe report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products in the five major European countries.In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as LeadingMarketResearch's proprietary data files was conducted.
Chancroid
Chlamydia
Gonorrhea
Granuloma Inguinale
Herpes I/II
Lymphogranuloma
Mycoplasma
Papillomavirus
Syphilis
Trichomonas VaginalisThe report provides test volume and sales forecasts by country and market segment, including:%li%Hospitals%li%Commercial/Private Labs%li%Public Health LabsIn addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of STD diagnostic products, by test and country. Also, the report examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies%li%Reviews features and operating characteristics of major analyzers used for STD testing; %li%Profiles key suppliers and potential market entrants developing innovative technologies and products; and analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues.MethodologyThe report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products in the five major European countries.In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as LeadingMarketResearch's proprietary data files was conducted.
I. Introduction
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Overview of Major Tests,
Technologies, and Instrumentation
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/COMBO, HIVAG/HIV NAT,
Western Blot, HTLV-I/II
2. ADENOVIRUS
3. AEROMONAS
4. ANTHRAX/BACILLUS ANTHRACIS
5. ARBOVIRUSES
6. BABESIOSIS
7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)
and Other Bartonella (Rochalimaea)
8. BLASTOCYSTIS HOMINIS
9. BRUCELLA
10. CAMPYLOBACTER
11. CANDIDA
Table of Contents (continued)
12. CHAGAS DISEASE
13. CHANCROID
14. CHLAMYDIA
15. CLOSTRIDIUM DIFFICILE
16. CORONAVIRUSES
17. COXSACKIEVIRUSES
18. CREUTZFELDT-JAKOB’S DISEASE
19. CRYPTOSPORIDIUM PARVUM
20. CYCLOSPORA CAYETANENSIS
21. CYTOMEGALOVIRUS
22. EBOLA VIRUS
23. E. COLI
24. ECHOVIRUS
25. ENCEPHALITIS
26. ENTEROVIRUSES
27. EPSTEIN-BARR VIRUS
28. GIARDIA LAMBLIA
29. GONORRHEA
30. GRANULOMA INGUINALE
31. HANTAVIRUS
32. HELICOBACTER PYLORI
33. HEPATITIS: HAV NAT, HBV NAT, HBS AG, HCV, HCV NAT,
Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT
34. HERPES SIMPLEX VIRUS
35. HUMAN HERPES VIRUS-6 (HHV-6)
36. INFLUENZA VIRUSES
37. LEGIONELLA
38. LYME DISEASE
39. LYMPHOGRANULOMA VENEREUM (LGV)
40. MALARIA
41. MEASLES (RUBEOLA)
42. MENINGITIS
43. MICROSPORIDIUM
44. MONONUCLEOSIS
45. MUMPS
46. MYCOPLASMA
47. PAPILLOMAVIRUSES
48. PARVOVIRUS B19
49. PNEUMONIA
50. POLYOMAVIRUSES
51. PSEUDOMONAS AERUGINOSA
52. RABIES
53. RESPIRATORY SYNCYTIAL VIRUS (RSV)
54. RHINOVIRUSES
55. ROTAVIRUS
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Overview of Major Tests,
Technologies, and Instrumentation
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/COMBO, HIVAG/HIV NAT,
Western Blot, HTLV-I/II
2. ADENOVIRUS
3. AEROMONAS
4. ANTHRAX/BACILLUS ANTHRACIS
5. ARBOVIRUSES
6. BABESIOSIS
7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)
and Other Bartonella (Rochalimaea)
8. BLASTOCYSTIS HOMINIS
9. BRUCELLA
10. CAMPYLOBACTER
11. CANDIDA
Table of Contents (continued)
12. CHAGAS DISEASE
13. CHANCROID
14. CHLAMYDIA
15. CLOSTRIDIUM DIFFICILE
16. CORONAVIRUSES
17. COXSACKIEVIRUSES
18. CREUTZFELDT-JAKOB’S DISEASE
19. CRYPTOSPORIDIUM PARVUM
20. CYCLOSPORA CAYETANENSIS
21. CYTOMEGALOVIRUS
22. EBOLA VIRUS
23. E. COLI
24. ECHOVIRUS
25. ENCEPHALITIS
26. ENTEROVIRUSES
27. EPSTEIN-BARR VIRUS
28. GIARDIA LAMBLIA
29. GONORRHEA
30. GRANULOMA INGUINALE
31. HANTAVIRUS
32. HELICOBACTER PYLORI
33. HEPATITIS: HAV NAT, HBV NAT, HBS AG, HCV, HCV NAT,
Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT
34. HERPES SIMPLEX VIRUS
35. HUMAN HERPES VIRUS-6 (HHV-6)
36. INFLUENZA VIRUSES
37. LEGIONELLA
38. LYME DISEASE
39. LYMPHOGRANULOMA VENEREUM (LGV)
40. MALARIA
41. MEASLES (RUBEOLA)
42. MENINGITIS
43. MICROSPORIDIUM
44. MONONUCLEOSIS
45. MUMPS
46. MYCOPLASMA
47. PAPILLOMAVIRUSES
48. PARVOVIRUS B19
49. PNEUMONIA
50. POLYOMAVIRUSES
51. PSEUDOMONAS AERUGINOSA
52. RABIES
53. RESPIRATORY SYNCYTIAL VIRUS (RSV)
54. RHINOVIRUSES
55. ROTAVIRUS
